No abstract

Purpose: To determine the 1-year outcomes of endoscopic pars plana vitrectomy (EPPV) and its impact on the corneal transplantation rate in patients with open-globe injury (OGI) and corneal opacity. Methods: This retrospective cohort study collected data between December 2018 and August 2021. All EPPVs were performed at a level I trauma center. Inclusion criteria were adult patients with a history of OGI complicated by corneal opacification that prevented fundus visualization. The main outcome measures were the rate of successful retinal reattachment, final visual acuity (VA), and number of patients who had penetrating keratoplasty (PKP) within 1 year of the OGI. Results: Ten patients (3 women; 7 men) with a mean age of 63.4 ± 22.7 years (SD) met the inclusion criteria. The indications for EPPV were intraocular foreign bodies in 2 patients, dense vitreous hemorrhage in 3 patients (1 with a retinal tear; 1 with a choroidal hemorrhage), and retinal detachment in 5 patients. The final VA ranged from 20/40 to no light perception. All 4 repaired detachments remained attached after 1 year. Corneal opacity was treated with PKP in 3 patients. Conclusions: Results indicate EPPV can be a useful tool to treat posterior segment pathology in patients with a recent OGI and corneal opacity. EPPV can help address posterior segment disease and postpone corneal transplantation until the visual potential can be fully determined. Larger prospective studies are needed.

Introduction: This study aimed to determine if Biosentry Plug Device (BP), a prophylactic sealant used to prevent pneumothorax after lung biopsies, reduced post-lung biopsy pneumothorax rates and other complications compared to no device utilization. Methods: This single institution, retrospective cohort study included patients who received a lung biopsy in the department of interventional radiology from May 1, 2015 to August 31, 2017. Data such as sex, race, ethnicity, COPD status, degree of lung bullae if present, smoking status, and use of BP were recorded. Decisions to use BP were based on operator preference. A chi squared analysis was used with a p value <0.05 considered significant. Results: The study included 521 patients who underwent a lung biopsy during the study timeframe. Of these, 74 (14.2%) received the BP device, while 447 (85.8%) did not. One-hundred ninety (36.4%) had a pneumothorax within 1 month of the lung biopsy. Of the total 190 that experienced pneumothorax, 36.7% of non-BP biopsies resulted in pneumothorax, while 35.1% of BP biopsies resulted in pneumothorax, p-value = 0.7970, degrees of freedom = 1. Conclusions: These findings indicate that BP may not reduce pneumothorax incidence nor limit the severity of complications in patients.

No abstract

culprit (Figure 2). Neither patient tolerated mosquito netting at night, and both wished to avoid nightly application of potential neurotoxins such as DEET. Safer insect repellents containing essential oils did not work. They therefore applied 1% IVM cream to their faces before bed and assessed themselves for new bites each morning. They treated for 3 weeks on, then off, and then on again. RESULTSBoth noted complete prevention of mosquito bites on the nights where 1% IVM cream was applied. Bites recurred after stopping 1% IVM cream. Complete prevention was again noted after restarting 1% IVM cream. DISCUSSIONTopical IVM prevented insect bites on the treated areas of the face. The pattern of recurrent bites after stopping IVM, and recurrent prevention after restarting IVM, provides further support for efficacy. Safety of topical 1% IVM cream is supported by its prolonged use as a treatment for lice and rosacea. 7,8 While